Roche (OTCQX:RHHBY) unit Genentech has completed
a supplemental Biologics License Application (sBLA) submission to the
FDA for Tecentriq (atezolizumab) in combination with
Avastin (bevacizumab) for the treatment of people with unresectable
hepatocellular carcinoma (HCC) who have not received prior systemic
therapy.
The FDA is reviewing the application under the Real-Time Oncology Review pilot program.
https://seekingalpha.com/news/3534561-genentech-submits-u-s-marketing-application-for-tecentriq-avastin
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.